| Unobservable Inputs and Assumptions Used in Determining the Fair Value of Biological Assets |
| | | | | | | | | | | | | | | | Accounting Policy
The Company defines biological assets as living plants up to the point of harvest. Biological assets are measured at fair value less costs to sell at the end of each reporting period in accordance with IAS 41 - Agriculture using the income approach. The Company utilizes an income approach to determine the fair value less cost to sell at a specific measurement date, based on the existing plants’ stage of completion up to the point of harvest. The Company cultivates cannabis and propagation plants biological assets. For cannabis plants, the stage of completion is determined based on the specific date of clipping the mother plant, the period-end reporting date, the average growth rate for the strain and facility environment and is calculated on a weighted average basis for the number of plants in the specific lot. | | | The following inputs and assumptions are all categorized within Level 3 on the fair value hierarchy and were used in determining the fair value of cannabis biological assets: | | | Inputs and assumptions | Description | Correlation between inputs and fair value | | | Average selling price per gram | Represents the average selling price per gram of dried cannabis net of excise taxes, where applicable, for the period for all strains of cannabis sold, which is expected to approximate future selling prices. | If the average selling price per gram were higher (lower), estimated fair value would increase (decrease). | | | | | | | | Weighted average yield per plant | Represents the weighted average number of grams of dried cannabis inventory expected to be harvested from each cannabis plant. | If the weighted average yield per plant was higher (lower), estimated fair value would increase (decrease). | | | Cost per gram to complete production | Based on actual production costs incurred divided by the grams produced in the period. | If the cost per gram to complete production was lower (higher), estimated fair value would increase (decrease). | | | | | | | | Stage of completion in the production process | Calculated by taking the weighted average number of days in production over a total average grow cycle of approximately twelve weeks. | If the number of days in production was higher (lower), estimated fair value would increase (decrease). | | | Production costs are capitalized to cannabis biological assets and include all direct and indirect costs relating to biological transformation. Costs include direct costs of production, such as labour, growing materials, as well as indirect costs such as indirect labour and benefits, quality control costs, depreciation on production equipment, and overhead expenses including rent and utilities. | | |
The following inputs and assumptions are all categorized within Level 3 on the fair value hierarchy and were used in determining the fair value of propagation plants biological assets: | | | Inputs and assumptions | Description | Correlation between inputs and fair value | | | Selling price per plant | Represents selling price per plant, which is based on committed purchase plans or approximate future selling price. | If selling price per plant were higher (lower), estimated fair value would increase (decrease). | | | Stage of completion in the production process | Calculated by taking the number of days in production over the promised date less the propagation date. | If the number of days in production was higher (lower), estimated fair value would increase (decrease). | | | Production costs are capitalized to propagation plants biological assets based on a rolling gross margin rate and includes all direct and indirect costs relating to biological transformation. Costs include direct costs of production, such as labour, growing materials, as well as indirect costs such as indirect labour and benefits, quality control costs, depreciation on production equipment, and overhead expenses including rent and utilities. | |
| | | | | | | | | | | | | | | | | | | Indefinite life intangible asset impairment testing | | | Goodwill impairment testing | | | | Australia Cannabis CGU | | | | Plant Propagation | September 30, 2025 | | | | | | | | | Terminal value growth rate | | | 2.5% | | | | 2.5% | | Discount rate | | | 10.0% | | | | 10.9% | EBITDA margin | | | (10.3)% - 1.7% | | | | 10% - 21.7% | | Fair value less cost to dispose | | | $1,158 | | | | $111,839 | | Carrying value | | | $14,374 | | | | $149,041 | Excess over carrying value | | | ($13,216) | | | | ($37,202) | | | | | | | | |
The key assumptions used in calculating the recoverable amount for the CGU and operating segment tested for impairment as at January 1, 2026 and January 1, 2025: | | | | | | | | | | | | | | | | | | | | Indefinite life intangible asset impairment testing | | Goodwill impairment testing | | | | | European Cannabis CGU | | Cannabis Operating Segment | | | January 1, 2026 | | | | | | | | | Terminal value growth rate | | | | 3.0% | | 2.5% | | | Discount rate | | | | 12.0% | | 15.3% | | | | | | | | | | EBITDA margin | | | | 0.2% - 6.1% | | 14% - 23.8% | | | Fair value less cost to dispose | | | | $61,867 | | $444,923 | | | Carrying value | | | | $54,275 | | $334,592 | | Excess over carrying value | | | | $7,592 | | $110,331 | |
| | | | | | | | | | | | | | | | | | | | | Indefinite life intangible asset impairment testing | | Goodwill impairment testing | | | | Australia Cannabis CGU | European Cannabis CGU | | Cannabis Operating Segment | | January 1, 2025 | | | | | | | | | Terminal value growth rate | | | 3.0% | 3.0% | | 2.5% | | | Discount rate | | | 10.3% | 13.3% | | 15.3% | | | | | | | | | | EBITDA margin | | | 0.4% - 3.7% | 5.2% - 11.4% | | 17.1% - 24.1% | | | Fair value less cost to dispose | | | $23,325 | $95,979 | | $403,767 | | | Carrying value | | | $14,338 | $40,869 | | $341,777 | | | Excess over carrying value | | | $8,987 | $55,110 | | $61,990 | |
|
| Changes in Carrying Value of Biological Assets |
The changes in the carrying value of biological assets during the period are as follows: | | | | | | | | | | | Note | | | | | $ | | Balance, March 31, 2024 | | 42,774 | | | | Production costs capitalized | | 116,915 | | | | | | | | Reclassified to discontinued operations, net | 6 | (50,788) | | | | | | | | | | | | Gain (loss) on changes in fair value of biological assets | | 168,111 | | | | Transferred to inventory upon harvest | | (225,627) | | | | Other | | (217) | | | Balance, March 31, 2025 | | 51,168 | | | | Production costs capitalized | | 100,226 | | | | | | | | Reclassified to discontinued operations, net | 6 | (44,321) | | | | | | | | | | | | Gain (loss) on changes in fair value of biological assets | | 116,131 | | | | Disposal of Plant Propagation | 6 | (25,848) | | | | Transferred to inventory upon harvest | | (176,899) | | | | Other | | (244) | | | Balance, March 31, 2026 | | 20,213 | | |
|
| Sensitivities and Impact of Changes in Significant Assumptions on the Fair Value of Biological Assets |
The following table highlights the sensitivities and impact of changes in significant assumptions on the fair value of biological assets grown at cannabis production facilities: | | | | | | | | | | | | | | | | | | | | | Significant inputs & assumptions(1) | Range of inputs | Sensitivity | Impact on fair value | | | March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | | | | | | | $ | $ | | | | | Average selling price per gram | $6.41 | | $6.61 | | Change of $1.00 per gram | 3,718 | | 3,401 | | | | | | Weighted average yield (grams per plant) | 114.07 | | 73.46 | | Change of 5 grams per plant | 1,436 | | 1,823 | | | | | | | | | | | | | | | Cost per gram to complete production | $1.09 | | $1.40 | | Change of $0.25 per gram | 930 | | 3,466 | | | | |
(1)Significant inputs and assumptions are in whole numbers as indicated. | | | | | | | | | | Significant inputs & key assumptions | Sensitivity | Decrease in fair value | | Discount rate | Increase of 0.5% | $4,848 | | Total revenue | Decrease of 1% | $18,101 | | EBITDA margin | Decrease of 1% | $3,288 |
|